UTTARABANK: Q3 Financials28 Oct 2025
(Q3 Un-audited): Consolidated EPS was Tk. 1.63 for July-September 2025 as against Tk. 1.26 for July-September 2024; Consolidated EPS was Tk. 3.46 for January-September 2025 as against Tk. 3.26 for January-September 2024. Consolidated NOCFPS was Tk. 0.55 for January-September 2025 as against Tk. 8.23 for January-September 2024. Consolidated NAV per share was Tk. 29.67 as on September 30, 2025 and Tk. 25.55 as on September 30, 2024.
UTTARABANK: Board Meeting schedule under LR 16(1)22 Oct 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2025 at 3:00 PM to consider, among others, Un-audited financial statements of the Company for the Third Quarter (Q3) period ended September 30, 2025.
UTTARABANK: Buy Confirmation of a Director24 Jul 2025
Mr. Asif Rahman, a Director of the Company has completed his buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 03.06.2025.
UTTARABANK: Q2 Financials17 Jul 2025
(Q2 Un-audited): Consolidated EPS was Tk. 0.58 for April-June 2025 as against Tk. 1.42 for April-June 2024; Consolidated EPS was Tk. 1.82 for January-June 2025 as against Tk. 2.00 for January-June 2024. Consolidated NOCFPS was Tk. 1.90 for January-June 2025 as against Tk. 5.62 for January-June 2024. Consolidated NAV per share was Tk. 27.92 as on June 30, 2025 and Tk. 24.21 as on June 30, 2024.
UTTARABANK: Board Meeting schedule under LR 16(1)10 Jul 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on July 16, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended June 30, 2025.
UTTARABANK: Credit Rating Result02 Jul 2025
Emerging Credit Rating Limited (ECRL) has assigned Surveillance rating to the Company as "AA" in the long term and and "ST-2" for short term along with a Stable outlook based on audited financial statements up to December 31, 2024 and other relevant quantitative as well as qualitative information up to the date of rating.
UTTARABANK: Buy Declaration of a Director03 Jun 2025
Mr. Asif Rahman, a Director of the Company, has expressed his intention to buy 10,00,000 shares of the Company at prevailing market price (in the Public and/or Block Market) through Dhaka Stock Exchange PLC. within next 30 (thirty) working days.
UTTARABANK: Dividend Disbursement03 Jun 2025
The Company has informed that it has disbursed the Cash Dividend for the year ended December 31, 2024 to the respective shareholders.
UTTARABANK: Dividend Disbursement01 Jun 2025
The Company has informed that it has credited the Bonus Shares for the year ended December 31, 2024 to the respective shareholders' BO Accounts.
UTTARABANK: Q1 Financials13 May 2025
(Q1 Un-audited): Consolidated EPS was Tk. 1.46 for January-March 2025 as against Tk. 0.68 for January-March 2024; Consolidated NOCFPS was Tk. 0.65 for January-March 2025 as against Tk. 5.80 for January-March 2024. Consolidated NAV per share was Tk. 33.75 as on March 31, 2025 and Tk. 28.29 as on March 31, 2024.
UTTARABANK: Board Meeting schedule under LR 16(1)06 May 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on May 12, 2025 at 2:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended March 31, 2025.
UTTARABANK: Resumption after record date20 Apr 2025
Trading of the shares of the company will resume on 21.04.2025.
UTTARABANK: Suspension for Record date17 Apr 2025
Trading of the shares of the company will remain suspended on record date i.e., 20.04.2025.
UTTARABANK: Spot News15 Apr 2025
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 16.04.2025 to 17.04.2025 and trading of the shares will remain suspended on record date i.e., 20.04.2025.